Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

35 Sökresultat.
Relevans Bedömning Nya först Gamla först

Hypersensitivity/ Anaphylaxis Evaluation Mepolizumab HES NCT00086658 - Hypersensitivity/ Anaphylaxis Evaluation

- 2021-09-20 - 1 Formulär, 1 Item-grupp, 53 Dataelement, 1 Språk
Item-grupp: evaluation Hypersensitivity
Study part: Hypersensitivity/ Anaphylaxis Evaluation.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

History of Hypersensitivity Mepolizumab HES NCT00086658 - History of Hypersensitivity/ Anaphylaxis related medical conditions

- 2017-06-05 - 1 Formulär, 2 Item-grupper, 17 Dataelement, 1 Språk
Item-grupper: medical history hypersensitivity, medical history hypersensitivity
Study part: History of Hypersensitivity/ Anaphylaxis related medical conditions.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Genetic Screening For HLA-B*5701 n Patients with HIV Week 1 NCT00340080 - Genetic Screening For HLA-B*5701 Week 1 NCT00340080

- 2017-06-20 - 1 Formulär, 1 Item-grupp, 18 Dataelement, 1 Språk
Item-grupp: Week 1
NCT00340080 / VIIV-CNA106030 https://clinicaltrials.gov/ct2/show/NCT00340080 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Week 1 Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Genetic Screening For HLA-B*5701 n Patients with HIV Week 2 NCT00340080 - Genetic Screening For HLA-B*5701 Week 2 NCT00340080

- 2017-06-20 - 1 Formulär, 1 Item-grupp, 18 Dataelement, 1 Språk
Item-grupp: Week 2
NCT00340080 / VIIV-CNA106030 https://clinicaltrials.gov/ct2/show/NCT00340080 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Week 2 Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Genetic Screening For HLA-B*5701 in Patients with HIV Week 6 NCT00340080 - Genetic Screening For HLA-B*5701 Week 6 NCT00340080

- 2017-04-19 - 1 Formulär, 1 Item-grupp, 18 Dataelement, 1 Språk
Item-grupp: Week 6
NCT00340080 / VIIV-CNA106030 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Week 6 Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Genetic Screening For HLA-B*5701 in Patients with HIV ABC-Containing Product Discontinuation NCT00340080 - Genetic Screening For HLA-B*5701 ABC-Containing Product Discontinuation NCT00340080

- 2017-04-19 - 1 Formulär, 1 Item-grupp, 10 Dataelement, 1 Språk
Item-grupp: ABC-Containing Product Discontinuation
NCT00340080 / VIIV-CNA106030 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: ABC-Containing Product Discontinuation Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Genetic Screening For HLA-B*5701 in Patients with HIV ABC-Containing Product NCT00340080 - Genetic Screening For HLA-B*5701 ABC-Containing Product NCT00340080

- 2017-04-19 - 1 Formulär, 1 Item-grupp, 16 Dataelement, 1 Språk
Item-grupp: ABC-Containing Product
NCT00340080 / VIIV-CNA106030 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: ABC-Containing Product Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

HLA-B*5701 And Hypersensitivity To Abacavir ABC Hypersensitivity NCT00373945

- 2017-04-12 - 1 Formulär, 8 Item-grupper, 90 Dataelement, 1 Språk
Item-grupper: Date of Visit/Assessment, Exposure to Abacavir, Symptoms associated with this hypersensitivity reaction, HRS Vital Signs, Antiretroviral Therapy, Concomitant Medication (ABCMED), CDC, ABC HSR Source
A Retrospective Case-Control Study to Estimate the Sensitivity and Specificity of a Pharmacogenetic Marker (HLA-B*5701) in Subjects With and Without Hypersensitivity to Abacavir Assessment: ABC Hypersensitivity NCT00373945 / VIIV-ABC107442 Annotated Design For Trial:abc442_lgm Protocol:ABC107442 Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus I, Phase: 4, Clinical Study ID: ABC107442, Sponsor: ViiV

HLA-B*5701 And Hypersensitivity To Abacavir LOGs NCT00373945

- 2017-04-12 - 1 Formulär, 5 Item-grupper, 95 Dataelement, 1 Språk
Item-grupper: Date of Visit/Assessment, Non Serious Adverse Event, Serious Adverse Events, Concomitant Antiretroviral Therapy, Concomitant Medications (CONMEDS)
A Retrospective Case-Control Study to Estimate the Sensitivity and Specificity of a Pharmacogenetic Marker (HLA-B*5701) in Subjects With and Without Hypersensitivity to Abacavir Assessment: LOGs NCT00373945 / VIIV-ABC107442 Annotated Design For Trial:abc442_lgm Protocol:ABC107442 Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus I, Phase: 4, Clinical Study ID: ABC107442, Sponsor: ViiV

Genetic Screening For HLA-B*5701 Pregnancy Notification Form NCT00340080

- 2017-06-20 - 1 Formulär, 2 Item-grupper, 33 Dataelement, 1 Språk
Item-grupper: Pregnancy Notification Form, Drug exposures
NCT00340080 / VIIV-CNA106030 https://clinicaltrials.gov/ct2/show/NCT00340080 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Pregnancy Notification Form Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Genetic Screening For HLA-B*5701 in Patients with HIV Study Conclusion NCT00340080 - Genetic Screening For HLA-B*5701 Study Conclusion NCT00340080

- 2017-04-25 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Study Conclusion
NCT00340080 / VIIV-CNA106030 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Study Conclusion Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Genetic Screening For HLA-B*5701 in Patients with HIV Serious Adverse Events NCT00340080 - Genetic Screening For HLA-B*5701 Serious Adverse Events NCT00340080

- 2017-04-25 - 1 Formulär, 1 Item-grupp, 55 Dataelement, 1 Språk
Item-grupp: Serious Adverse Events
NCT00340080 / VIIV-CNA106030 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Serious Adverse Events Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial